Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to con... by Philip J Mease, Dafna D Gladman, Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, Daniela Graham, Cunshan Wang, Joseph C Cappelleri, Thijs Hendrikx, Ming-Ann Hsu

Get full text